Deal facts
- Buyer
- GSK plc
- Target
- 35Pharma Inc.
- Deal value
- USD 950,000,000
- Announced
- 15 April 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- Canada
- Consideration
- cash
Sources
GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic acquisition with full cash consideration. Both the announcement and completion of the deal occurred on 15 April 2026, indicating an immediate closing without a prolonged regulatory waiting period. This acquisition represents a significant capital deployment into the biopharmaceutical sector by the buyer.
The deal was finalised on the same day it was announced, suggesting a streamlined approval process or prior regulatory clearance. No specific details regarding the target's revenue or the specific assets acquired were reported in the available data. The transaction is now complete, with GSK plc having taken full ownership of the Canadian entity. The parties have concluded all necessary legal and financial obligations required to transfer control of the business.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
GSK plc to acquire 35Pharma Inc.
{ "headline": "GSK completes acquisition of 35Pharma Inc.", "issuer": "GSK (GSK)", "announcement_date": "2026-04-15T07:12:00", "category_code": "Completion of Acquisition", "body": "Disclaimer* \n\n Issued: 15 April 2026, London UK \n\n \n\n GSK completes acquisition of 35Pharma Inc. \n\n \n\n \n\n \n\n GSK plc (LSE/NYSE: GSK) today announced the completion of its acquisition of
LSE RNS
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Cronos Group Inc. to acquire CanAdelaar B.V.
Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…
- Buyer
- Cronos Group Inc.
- Target
- CanAdelaar B.V.
- Deal value
- EUR 57,500,000
- Deal type
- strategic acquisition
Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.
Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…
- Buyer
- Alaunos Therapeutics, Inc.
- Target
- Velaris Therapeutics, Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
STERIS Corporation to acquire Xodus Medical, Inc.
STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…
- Buyer
- STERIS Corporation
- Target
- Xodus Medical, Inc.
- Deal value
- USD 2,100,000,000
- Deal type
- strategic acquisition
Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC
Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…
- Buyer
- Hepion Pharmaceuticals, Inc.
- Target
- Gravitas Life Sciences, LLC
- Deal value
- USD 4,250,000
- Deal type
- strategic acquisition
Buyer history
GSK plc
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive